On March 29, 2018 Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD) a clinical-stage biopharmaceutical company focused on the development of CART-cell therapies, reported that the company will present updates on its ongoing Phase I clinical trials at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held April 14–18, 2018, in Chicago (Press release, Celyad, MAR 29, 2018, View Source [SID1234532518]). Poster presentations will feature updated data from Celyad’s THINK[1] trial, the new SHRINK[2] and LINK[3] trials in metastatic colorectal cancer, as well as data from a preclinical study showing that the addition of either the CD28 or 4-1BB co-stimulatory domains to CYAD-01 construct brings no benefit in terms of in vitro activity of the receptor.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details:
Poster Title: The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D chimeric antigen receptor T cell therapy (CYAD-01) in acute myeloid leukemia.
Poster Number: CT129
Session Title: Phase I Trials in Progress
Session Date & Time: Tuesday, April 17, 2018, 8:00 AM – 12:00 PM CDT
Location: Mc Cormick place south, Exhibit Hall A, Poster Section 42, Poster Board 12
Download the poster
Poster Title: The SHRINK clinical trial: A phase I study assessing the safety and clinical activity of multiple doses of an NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.
Poster Number: CT123
Session Title: Phase I Trials in Progress
Session Date & Time: Tuesday, April 17, 2018, 8:00 AM – 12:00 PM CDT
Location: Mc Cormick place south, Exhibit Hall A, Poster Section 42, Poster Board 6
Download the poster
Poster Title: The LINK clinical trial: A phase I study assessing the safety and clinical activity of multiple hepatic transarterial administrations of an NKG2D-based CAR-T therapy, CYAD-01, in patients with unresectable liver metastases from colorectal cancer.
Poster Number: CT134
Session Title: Phase I Trials in Progress
Session Date & Time: Tuesday, April 17, 2018, 8:00 AM – 12:00 PM CDT
Location: Mc Cormick place south, Exhibit Hall A, Poster Section 42, Poster Board 17
Download the poster
Poster Title: NKG2D as a chimeric antigen receptor – DAP 10 provides optimal co-stimulation for NKG2D based CARs.
Session Title: Adoptive Cell Therapy 3
Poster Number: 3583
Session Date & Time: Tuesday, April 17, 2018, 8:00 AM – 12:00 PM CDT
Location: Mc Cormick place south, Exhibit Hall A, Poster Section 24, Poster Board 21